Intraoperative detection of clear cell renal cell carcinoma with 111 In-girentuximab-IRDye800CW: proof of principle study

Abstract

The aim of this study is to show the feasibility and safety of CAIX-targeted dual-modality imaging in ccRCC. Seven days before partial or radical nephrectomy, patients were injected with 100MBq 111 In-girentuximab-IRDye800CW (5–50 mg). After 4 days a SPECT/CT was obtained. After 7 days surgery was performed with the use of intraoperative gamma probe detection and fluorescence imaging. Fifteen patients were included, of which three had a CAIX-negative tumor. No study-related serious adverse events were observed. All ccRCC were visualized on the SPECT/CT scan and localized by intraoperative gamma probe detection (mean T:N ratio 2.5 ± 0.8), while mean T:N ratios were 1.0 ± 0.1 in CAIX-negative tumors. All ccRCC were hyperfluorescent and in one patient fluorescence imaging revealed a positive surgical margin. Conclusion: Tumor-targeted dual-modality imaging using 111 In-girentuximab-IRDye800CW is safe and can be used for intraoperative ccRCC detection.